U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07913529) titled 'Time Course of Clozapine-associated Agranulocytosis Over 19 Years' on Oct. 28.
Brief Summary: Clozapine is the most effective antipsychotic medication for treatment-resistant schizophrenia, but it carries a rare, potentially life-threatening risk of agranulocytosis (a severe drop in white blood cells), which is why patients undergo regular blood monitoring. Most cases occur in the first months of treatment, and it remains unclear how much risk persists after the first year. This retrospective study will use existing electronic health records from Sheba Medical Center (February 2007 to August 2026) to describe when agranulocytosis occ...